Concord Medical Services (NYSE:CCM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Concord Medical Services (NYSE:CCM) to a hold rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Concord Medical Services in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Concord Medical Services has an average rating of “Sell”.

Concord Medical Services Trading Down 2.1%

CCM stock opened at $4.66 on Friday. The business’s 50-day moving average is $4.62 and its two-hundred day moving average is $4.29. The company has a quick ratio of 0.46, a current ratio of 0.48 and a debt-to-equity ratio of 1.33. Concord Medical Services has a 1 year low of $3.18 and a 1 year high of $6.98.

About Concord Medical Services

Concord Medical Services Holdings Limited is one of China’s leading providers of radiotherapy equipment and oncology services. The company specializes in supplying and operating advanced radiotherapy machines, including linear accelerators, computed tomography (CT) simulators and brachytherapy units, to public and private hospitals. Through its integrated service model, Concord Medical Services delivers treatment planning, machine maintenance and clinical support to enhance the precision and effectiveness of cancer therapies.

Founded in 1997 and headquartered in Beijing, Concord Medical Services has developed an extensive network of oncology centers across major cities and provinces in China.